A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the tolerability and safety of Sildenafil Citrate 20mg Sublingual tablet, as well as a possible superiority expressed by the faster onset of action compared to Viagra ® 50mg tablet Coated in erectile dysfunction.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Titration Study to Evaluate Efficacy and Satisfaction of Viagra in Men With Erectile Function.

NCT00249730

Impotence

COMPLETED PHASE4

Effects of Sildenafil on Penile Vascular Function in Hypertensive Men With Erectile Dysfunction

NCT02620995

Arterial Hypertension Erectile Dysfunction

COMPLETED PHASE4

Assessment Of Sildenafil On Erectile Function And Intercourse Satisfaction And To Validate A New Subject Questionnaire

NCT00147628

Impotence

COMPLETED PHASE4

A Study Of The Safety and Efficacy Of Viagra In Men With Erectile Dysfunction Who Do Not Self Identify.

NCT00343200

Impotence

COMPLETED PHASE4

Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Versus To Viagra® Oral Tablet.

NCT01254383

Erectile Dysfunction

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Phase III clinical trial, comparative, open, multicenter, prospectively, with random inflow of 78 patients evaluable male patients with erectile dysfunction with IIEF-5 score in between 13 and 24, corresponding to mild or mild to moderate to evaluate the efficacy and safety as well as a possible superiority expressed by the faster onset of action onset of action of study medication.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Erectile Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sildenafil Citrate 20mg Tablet Sublingual

Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.

Group Type EXPERIMENTAL

Viagra ® 50mg tablet Coated

Intervention Type DRUG

Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.

Viagra ® 50mg tablet Coated

Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.

Group Type ACTIVE_COMPARATOR

Sildenafil Citrate 20mg Tablet Sublingual

Intervention Type DRUG

Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sildenafil Citrate 20mg Tablet Sublingual

Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.

Intervention Type DRUG

Viagra ® 50mg tablet Coated

Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over 18 years;
* Patients with erectile dysfunction of various etiologies (organic, psychogenic and mixed) for at least 6 months;
* Patients with scores in the IIEF-5 between 13 and 24, which correspond to mild or mild to moderate;
* Relationship stable for at least 6 months;
* Patients should be kept with libido;
* Education at least 4 years;
* Do not use sildenafil, vardenafil, tadalafil, lodenafil, injection therapy or vacuum devices up to 72 hours before the screening visit;
* Functions hepatic, hematological, hormonal and renal within the following benchmarks:
* Creatinine: 0.6 to 1.10 mg / dl;
* Urea: 10 - 50mg/dl;
* TGP: up to 40 U / L;
* TGO: ≤ 34 U / L;
* Prolactin: 2.3 to 11.5 ng / ml Men
* Total Testosterone: 241 to 827 ng/100 ml - Men
* Blood glucose: 70 mg / dl and 99mg/dl.

Exclusion Criteria

* Patients who have failed treatment with inhibitors of phospho-diesterase inhibitors;
* Patients undergoing radical prostatectomy;
* Patients with hypersensitivity to any component of the formula;
* Presence of genital deformities or other disorders that prevent intercourse;
* Operations prior to penile erectile dysfunction or premature ejaculation penis enlargement;
* Use of other treatments for erectile dysfunction or concomitant treatment with nitrates;
* Myocardial infarction or cerebrovascular accident (CVA) for less than 6 months;
* Heart disease or uncontrolled serious;
* Injury cord injury;
* Multiple sclerosis;
* Retinitis pigmentosa;
* Neoplasms known in business and / or treatment;
* History of severe anaphylactic reactions and disease Steven-Johnson;
* Participation in a clinical study in the 2 months prior to inclusion;
* Patients who are making use of antiretrovirals;
* Any other disease or condition is not matched that in the opinion of the investigator, could lead to increased risk for the patient or who makes it inappropriate for this study;
* Comorbidities such as diabetes mellitus, malignant hypertension, blood pressure (BP), systolic\> 170 mmHg, diastolic BP levels\> 110 mmHg, blood pressure \<80 x 50 mmHg, significant cardiovascular disease, alcohol or drugs, or other disorders important.

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No